EULAR 2024

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

Difference in axial involvement in axSpA and axPsA

Tapering or even stopping TNF inhibitors in pts. with…

JAK inhibitors in GCA - a good opportunity?

Deeper B-cell depletion

Avoiding overdiagnosis in axSpA

Sooner or later - when therapy with biologics?

Factors associated with spinal progression in axSpA

Uterine inflammation in the pathogenesis in axSpA

Neuroinflammation as possible cause of intestinal…

Treat-to-target approach to induce sustained clinical…

Minimal spinal radiographic progression with…

What advances the radiographic progression? IL-17A vs.…

Minimale Röntgenprogression der Wirbelsäule unter…

Approccio treat-to-target per indurre una remissione…

Treat-to-target bei der axSpA - a long way to go!

Was treibt die Röntgenprogression an? IL-17A vs. TNF…

Ruolo della neuroinfiammazione della patogensi…

Vermeidung von Überdiagnose bei axSpA

Ruolo dell’infiammazione uterina nella patogenesi…

Difference in axial involvement in axSpA and axPsA

Subclinical PsA - where is the border?

IL-17 inhibition & new molecules

A new injection for knee osteoarthritis

Treatment strategy in early PsA - TnF inhibitors or…

Small molecules with a better enthesitis efficacy - new…

12-weeks results from the PRO-SPIRIT study

The JAK family is growing. Another Tyk2 inhibitor: safe…

Sonelokimab, a new molecule for IL-17A & IL-17F…

A mouse model for PsA and PsO!

Managing comorbidities in PsA

Early prediction by FAPI-PET in PsA

The difficult cases in PsA

Which treatment to prevent PsA from PsO?

Cardiovascular outcome in PsA - TnF vs. IL-17…

A lot of steroids always help - no matter the…

Kleine Moleküle mit besserer Enthesitiswirkung - neue…

Valutazione della risposta a due anni di trattamento…

Frühe Prädiktion durch FAPI-PET bei PsA

Quel traitement pour prévenir l’évolution du psoriasis…

Risultati a 12 settimane dello studio di Real World…

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor:…

Viel Kortison hilft immer - Begleittherapie egal...

Sonelokimab, ein neues Molekül zur IL-17A- &…

Rhumatisme psoriasique débutant : anti TNF ou pas?

Handling cardiovascular risks in RA

Deeper B-cell depletion

JAK inhibitors in GCA - a good opportunity?

ARCTIC REWIND - Tapering not recommended in patients on…

Debate on regulatory safety measures for JAKies based…

Tapering of TNF Inhibitors in RA Patients with…

A model to predict progression from palindromic…

Anti-citrullinated protein antibody (ACPA) does not…

No new safety signals from the JAK-POT study

Potential new treatment class in RA

Abatacept vs adalimumab in dual seropositive RA…

Debate on therapeutic drug monitoring

Statins in RA - who benefits?

Good news in RA

Real-world data on safety of etanercept biosimilar

ARCTIC REWIND – dosereduksjon og seponering anbefales…

Keine neuen Safety-Signale aus der JAK-POT Studie

Debatt om bruk av therapeutic drug monitoring (TDM,…

Abatacept vs adalimumab en pacientes con AR doble…

En ny JAK hemmer undersøkt i en fase III studie I Kina

Debatt om regulatoriske krav om sikkerhet ved bruk av…

Reducción y suspensión de los inhibidores del TNF en…

Un modelo para predecir la progresión del reumatismo…

The role of rheumatoid factor from early to late

AI in rheumatology

How to treat Lupus: What's on the horizon?